智通财经APP讯,恒瑞医药(01276)发布公告,近日,公司收到国家药品监督管理局(以下简称“国家药监局”)的通知,批准公司布比卡因脂质体注射液新增适应症。批准的适应症:成人腘窝坐骨神经阻滞产生术后区域镇痛;成人收肌管阻滞产生术后区域镇痛。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.